Product Introduction

OBEDA® is a prescription-only injectable medicine containing semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. Manufactured in India by Dr. Reddy’s Laboratories Limited, the product is supplied as a prefilled pen containing 1.5 mL of solution equivalent to 2 mg of semaglutide.

The pack indicates selectable doses of 0.25 mg and 0.5 mg, with dose delivery in these increments only. It is intended for subcutaneous administration according to a specialist's prescription. The packaging states that the pen is for single-patient use only and includes six BD Ultra-Fine™ 32G needles and product literature.

Important: The package specifically warns that the medicine is to be sold by retail only on the prescription of an endocrinologist or internal medicine specialist. Dispensing and use must follow the applicable prescription and regulatory requirements.

Uses

Semaglutide medicines may be prescribed for specific metabolic conditions, depending on the approved indication for the particular product and local prescribing information.

• Blood glucose management: Semaglutide is used in certain formulations to improve glycaemic control in adults with type 2 diabetes.

• Metabolic management: Some semaglutide formulations have an approved role in chronic weight management for eligible patients. This indication must not be assumed for OBEDA without confirmation from its current Indian prescribing information.

• Specialist-directed treatment: The exact indication, suitability and treatment plan must be determined by the prescribing specialist.

Do not use OBEDA for type 1 diabetes or diabetic ketoacidosis unless a specialist is addressing a separate, specifically indicated clinical need. It is not a substitute for insulin when insulin is medically required.

Key Ingredients & Full Ingredients

Active ingredient

• Semaglutide: 1.34 mg per mL.

• Each 1.5 mL prefilled pen contains a total of 2 mg semaglutide.

Inactive ingredients listed on the packaging

• Disodium phosphate dihydrate: 1.42 mg per mL.

• Propylene glycol: 14.0 mg per mL.

• Phenol: 5.50 mg per mL.

• Water for injection.

• Hydrochloric acid or sodium hydroxide may be added to adjust pH.

The amounts above are transcribed from the supplied packaging images. Confirm the complete formulation against the package insert before publishing or dispensing.

Benefits

• Provides semaglutide in a prefilled injection pen for subcutaneous administration.

• Offers selectable 0.25 mg and 0.5 mg doses as indicated on the packaging.

• Uses a GLP-1 receptor agonist to support glucose-dependent insulin secretion and glucose regulation.

• May help improve blood glucose control when prescribed for an appropriate indication.

• The pen format and included needles support administration according to the product instructions.

• Includes product literature for patient guidance.

Benefits depend on the approved indication, prescribed dose, adherence and individual response. Results are not guaranteed.

Side Effects

Potential adverse effects of semaglutide include:

Common effects

• Nausea and vomiting.

• Diarrhoea or constipation.

• Abdominal discomfort, bloating or indigestion.

• Reduced appetite.

Serious effects requiring prompt medical assessment

• Persistent or severe abdominal pain, which may indicate pancreatitis.

• Severe or persistent vomiting or diarrhoea, which can cause dehydration and kidney problems.

• Symptoms of gallbladder disease, such as upper abdominal pain, fever or jaundice.

• Allergic reactions, including facial or throat swelling or difficulty breathing.

• Hypoglycaemia, particularly when used with insulin or sulfonylureas.

• Sudden changes in vision in a patient with diabetes, which warrant urgent clinical review.

This is not a complete list. Refer to the current package insert and seek medical advice about any new or worsening symptoms.

Product Form

• Dosage form: Sterile solution for injection.

• Presentation: Prefilled injection pen.

• Strength: 2 mg/1.5 mL (1.34 mg/mL).

• Administration route: Subcutaneous injection only.

• Pack contents: One semaglutide prefilled pen, six BD Ultra-Fine™ 32G needles and product literature, as stated on the pack.

• Patient use: Single-patient use only.

How to Use

1. Obtain a valid prescription. Use only under the supervision of the specialist specified on the packaging.

2. Read the medication guide. Review the instructions supplied with the pen and have a pharmacist or healthcare professional demonstrate its use.

3. Check the pen. Confirm the medicine name, strength, expiry date, solution appearance and package integrity. Do not use it if the seal is broken before first use or the solution appears abnormal.

4. Follow the prescribed dose. The pack identifies 0.25 mg and 0.5 mg dose increments. Do not independently select a dose, increase the dose or change the treatment schedule.

5. Administer subcutaneously. Use only the approved injection sites and technique described in the product instructions. Do not inject into a vein or muscle.

6. Use a new needle for each injection. Never share the pen, even if the needle is changed.

7. Dispose of the needle safely. Use an appropriate sharps container and follow local disposal guidance.

Missed dose, dose changes and overdose: Follow the official patient leaflet and contact the prescribing specialist or pharmacist for advice. Do not take an extra dose to compensate for a missed one.

How It Works

Semaglutide mimics the activity of glucagon-like peptide-1 (GLP-1), a naturally occurring hormone involved in glucose regulation and appetite signalling.

• Glucose-dependent insulin secretion: Helps the pancreas release insulin when blood glucose is elevated.

• Glucagon regulation: Reduces inappropriate glucagon secretion, helping limit excess glucose production by the liver.

• Gastric emptying: Can slow stomach emptying, particularly early in treatment, which may affect post-meal glucose levels and gastrointestinal tolerance.

• Appetite signalling: Acts on pathways involved in appetite and satiety.

These effects can contribute to improved blood glucose control in appropriately selected patients. The clinical effects and approved uses depend on the specific product, its prescribing information and the patient's condition.

3. Medical & Safety Information

Safety Advice

• Prescription requirement: The package states that retail sale is restricted to prescriptions from an endocrinologist or internal medicine specialist.

• Pregnancy: Semaglutide is generally not recommended during pregnancy. Anyone who is pregnant, planning pregnancy or breastfeeding should discuss treatment with their specialist before use. Semaglutide is generally discontinued at least two months before a planned pregnancy; the prescriber must advise on the appropriate plan.

• Breastfeeding: Obtain specialist advice because product-specific information and the clinical circumstances determine whether treatment is appropriate.

• Alcohol: Alcohol may complicate blood glucose management and may worsen gastrointestinal symptoms. Discuss alcohol consumption with the treating clinician, especially when taking other glucose-lowering medicines.

• Driving and operating machinery: Semaglutide alone is not generally expected to impair driving directly, but hypoglycaemia can occur when it is combined with insulin or sulfonylureas. Do not drive if dizzy, unwell or experiencing low blood glucose.

• Kidney conditions: Severe vomiting or diarrhoea can lead to dehydration and worsening kidney function. Patients with kidney disease require appropriate medical monitoring.

• Liver conditions: Discuss existing liver disease and all other medical conditions with the prescriber; do not assume the medicine is suitable without an individual assessment.

• Pancreatitis: Tell the specialist about any history of pancreatitis. Seek urgent assessment for persistent, severe abdominal pain.

• Gallbladder disease: Report previous gallstones or gallbladder problems.

• Diabetic eye disease: Patients with diabetic retinopathy or sudden changes in vision should inform their specialist.

• Thyroid tumour risk: Discuss any personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2) with the prescriber. Semaglutide product warnings and contraindications must be checked against the applicable Indian prescribing information.

• Children: Keep the pen and needles out of children's reach. Use in children only if specifically authorised by the applicable product information and specialist.

Quick Tips

• Store the unopened pen in a refrigerator at 2°C to 8°C. Do not freeze.

• According to the supplied pack, after first use the pen may be stored for 56 days at a temperature not exceeding 30°C or in a refrigerator at 2°C to 8°C.

• Protect the pen from inappropriate storage conditions and follow the complete leaflet for light exposure and handling.

• Never share the pen with another person.

• Keep a record of the prescribed dose and injection schedule.

• Maintain any recommended nutrition, physical activity and blood glucose monitoring plan.

• Contact the prescriber before combining semaglutide with other diabetes medicines or changing an existing treatment.

Fact Box

Dietary restrictions: There is no universal food restriction solely because of semaglutide, but a clinician may recommend an individual meal plan. Follow any dietary advice provided for the underlying condition.

Interaction with Drugs

Important interactions and precautions include:

• Insulin and sulfonylureas: May increase the risk of hypoglycaemia; the prescriber may need to adjust doses.

• Other semaglutide products or GLP-1 receptor agonists: Do not combine without explicit specialist direction.

• Medicines taken by mouth: Delayed gastric emptying may affect the absorption or timing of certain oral medicines. Discuss medicines requiring close monitoring with a pharmacist.

• Warfarin and other medicines requiring monitoring: Additional monitoring may be appropriate when changes in gastrointestinal function or food intake could affect treatment.

• Medicines associated with dehydration or kidney stress: Severe gastrointestinal side effects may increase the risk of kidney complications, particularly in vulnerable patients.

Provide the prescriber with a complete list of prescription medicines, over-the-counter products and supplements. Do not stop or adjust any medicine without professional advice.

4. Business Details

Manufacturer, Importer, and Marketer

Manufacturer details (transcribed from the supplied packaging):

• Brand: OBEDA®

• Manufacturer: Dr. Reddy’s Laboratories Limited

• Importer: Not identified on the supplied packaging images.

• Marketer: A separate marketer is not identified on the supplied packaging images.

• Website: iMEDICART.com

Packaging warning: “To be sold by retail on the prescription of endocrinologist or internal medicine specialists only.”

The manufacturer details above are transcribed from the supplied images. Verify the legal manufacturer name, address, current licence details and any additional importer or marketer information against the physical pack before publishing the listing.

5. FAQs

1. What is OBEDA Semaglutide Injection used for?

OBEDA contains semaglutide, a GLP-1 receptor agonist. Semaglutide is used in certain approved formulations for type 2 diabetes and, for some specific products, chronic weight management. Confirm OBEDA's exact approved indication with the prescribing specialist and its current Indian package insert.

2. What strengths or doses are shown on the OBEDA pack?

The pack states a total content of 2 mg semaglutide in 1.5 mL, at a concentration of 1.34 mg/mL. It also identifies selectable doses of 0.25 mg and 0.5 mg. The prescribed dose and schedule must be determined by the specialist.

3. How should OBEDA be stored?

Store the pen refrigerated at 2°C–8°C before first use and do not freeze it. The supplied packaging states that after first use it may be stored for 56 days at a temperature not exceeding 30°C or in a refrigerator at 2°C–8°C. Follow the complete leaflet for any additional storage requirements.

4. What are the common side effects of semaglutide?

Common side effects include nausea, vomiting, diarrhoea, constipation and abdominal discomfort. Severe persistent abdominal pain, allergic reactions, dehydration or sudden changes in vision require prompt medical assessment.

5. Can OBEDA be used without a prescription?

No. The packaging specifically restricts retail sale to prescriptions from an endocrinologist or internal medicine specialist. It should not be self-prescribed or used solely for weight loss without specialist assessment.